Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Top 5 Biosimilar Articles for the Week of September 4

September 8th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of September 4, 2023.

The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs

September 7th 2023

By Luke Halpern

Article

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

CVS Launches New Biosimilars Brand

September 6th 2023

By Skylar Jeremias

Article

CVS Health Corporation launched Cordavis, a new subsidiary that will work with manufacturers to commercialize and coproduce biosimilars, beginning with an adalimumab product.

Biosimilars Business Roundup For August 2023—Podcast Edition

September 5th 2023

By Justina Petrullo

Podcast

On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.

Higher Risk of Discontinuation During Biosimilar Switching Found Among Women

September 5th 2023

By Justina Petrullo

Article

Switching from reference to biosimilar adalimumab was found to be safe and effective. Researchers cautioned that female patients may be at higher risk of discontinuation compared with their male counterparts.

BioRationality: First Price Reductions Under the IRA—3 Biologics With No Biosimilars

September 4th 2023

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, reacts to CMS' list of the first 10 drugs chosen for price negotiation under the Inflation Reduction Act (IRA), including 3 biologics with no biosimilar competition.

Alvotech Earnings Jump Nearly 600% Year Over Year

September 2nd 2023

By Skylar Jeremias

Article

Alvotech’s revenues for the first 6 months of 2023 reached $22.7 million, a nearly 600% year-over-year increase.

The Top 5 Biosimilar Articles for the Week of August 28

September 1st 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of August 28, 2023.

Biosimilars Business Roundup: August 2023

August 31st 2023

By Skylar Jeremias

Article

After a busy July, August brought hope for the biosimilars industry’s future, with the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and several analyses about the health of the market.

TNFi Switching Is Safe, Effective for Rheumatoid Arthritis, Study Suggests

August 30th 2023

By Justina Petrullo

Article

Single switching between approved biologics and biosimilars of tumor necrosis factor inhibitors (TNFis) were found to be safe and effective for rheumatoid arthritis.